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The polysaccharide chitosan (CS) is known to be an excel-
lent material for drug preparation. CS is a plentiful natural
biopolymer and is non-toxic, biocompatible and biodegrad-
able.1—3) These properties are important for materials that are
implanted in the body, because such materials must avoid the
host’s defense system during their long-term contact with liv-
ing structures. CS has been investigated as a unique vehicle
for the sustained delivery of drugs,4,5) in particular, the prepa-
ration of CS microspheres has been studied.5—7) We investi-
gated the preparation of a suitable vehicle, such as micros-
pheres, for intra-articular injection in rheumatoid arthritis to
allow sustained drug delivery. Lu et al.8) reported that CS
could act on the epiphyseal cartilage and augment wound
healing of articular cartilage. Therefore, it might be useful in
healing wounds in articular cartilage after fulfilling a role as
a vehicle for drug delivery. In a previous study, CS was
found to form gel spheres at around pH 9 in amino acid solu-
tion, despite usually forming a gel in solutions with a pH
.12.9) This is thought to be due to coacervation. Prepara-
tions made at a lower pH are preferable due to their effect on
the solubility or stability of the drug contained in the gel
beads and on the tissue into which they are injected. Further-
more, the release of drug from CS gel beads could be con-
trolled by the formation of a complex between chondroitin
sulfate and CS.10) Intra-articular injection of steroids is used
commonly in the treatment of rheumatoid arthritis. Under
such conditions, it is difficult to achieve a sustained intra-ar-
ticular drug level on the basis of drug solubility. During in
vivo degradation, drug release is governed by both diffusion
and biodegradation of the matrix. It is necessary to clarify
the relationship between in vivo biodegradability and drug
release profiles of CS gel beads under different conditions
(enzymes, dissolution medium, stirring strength, etc.), and
those in vitro. In this study, this relationship was investigated
by implanting novel CS gel beads into subcutaneous air
pouches (AP) prepared on the dorsal surface of mice.
MATERIALS AND METHODS
Materials CS with varying degrees of deacetylation
(70% (7B), 80% (8B), 90% (9B), 100% (10B)) was pur-
chased from Katokichi Co., Ltd., Japan. Prednisolone (PS)
and sodium alginate (300 cps) (Alg) were purchased from
Nacalai Tesque Inc., Japan. The other reagents were obtained
from Wako Pure Chemical Industries and Nacalai Tesque
Inc., Japan. 
Preparation of CS Gel Beads CS gel beads were pre-
pared as follows: CS (1% w/w) was dissolved in 0.1 M ac-
etate buffer (pH 4.5) and 1% PS was then added to the CS
solution. One gram of this suspension, theoretically contain-
ing 10 mg of PS, was dropped slowly into 20 ml of 10%
glycine solution (pH 9.0) using a pipette and left at room
temperature for 25 min. Hydrogel beads were formed sponta-
neously. Dried gel beads were obtained by drying the hydro-
gel beads at 37 °C for 24 h in a dish, before holding them
under vacuum in a desiccator in the presence of P2O5. The
dried gel beads retained PS above 95% of the theoretical total
amount and had a diameter of about 3.5 mm and glycin con-
tent of about 51% of their dry weight. The beads were then
implanted into mice as follows: the dried beads were washed
with distilled/demineralized water before implantation to re-
move glycine because of the effect of glycine on living tis-
sue. The hydrogel beads retained PS to about 80% of the the-
oretical total amount and had a diameter of 4.3 mm and
glycine content of ,1.56 mg (limit of detection). Glycine was
detected by a modification of the method of Watanabe and
Imai.11)
Preparation of Alg Gel Beads Alg (1% w/w) was dis-
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Chitosan (CS) gel beads were prepared in 10% amino acid solution (pH 9) and implanted into air pouches
(AP) prepared subcutaneously on the dorsal surface of mice. No inflammatory response was observed, and
degradation of the beads in the AP increased as their degree of deacetylation decreased. Degradation could be al-
tered by changing the nature of the CS or by increasing the CS concentration. The release of prednisolone (PS)
in vivo from CS gel beads was similar to the release in vitro. When a suspension of PS was injected into the AP,
the PS had almost completely disappeared 24 h after injection. Retention of PS in the AP was not increased by
using a viscous CS solution. Alginate (Alg) gel beads, which were not degraded, released PS slowly into the AP
over 3 d. The in vitro release profile of PS using 1% CS (deacetylation: 70% (7B) and 80% (8B)) and 1.5% CS
(deacetylation: 90% (9B)) gel beads was similar to that with Alg gel beads. However, the in vivo release of PS was
affected by the degradability of the gel beads. CS7B and 8B (1%) gel beads had released PS into the AP earlier
than 3 d according to their rate of degradation. CS9B (1.5%) gel beads were not degraded after 3 d and went on
to release PS into the AP for 3 d similar to the release profile of Alg gel beads. CS9B (2%) gel beads were also not
degraded after 3 d and the release of PS from these beads into the AP was sustained; 76% and 27% of adminis-
tered PS remained in the gel beads after 1 and 3 d, respectively. Therefore, degradation and drug release of CS
gel beads can be controlled by changing the structure of the gel matrix, which appears to make these beads a
promising biodegradable vehicle for sustained drug delivery.
Key words chitosan; biodegradation; sustained release; gel; amino acid; air pouch
solved in distilled/demineralized water, and 1% PS was then
added to the Alg solution. One gram of the suspension, theo-
retically containing 10 mg of PS, was dropped slowly into
0.1 M CaCl2 using a pipette and left at room temperature for
1 h. Hydrogel beads were formed spontaneously and retained
PS to about 90% of the theoretical total amount, with a diam-
eter of about 4.0 mm. The hydrogel beads were then im-
planted into mice. Dried gel beads were useful from the point
of view of preservation. However, dried Alg gel beads did
not swell well, even after soaking in water. Thus, in the case
of Alg, hydrogel beads were used for implantation.
Dissolution Test The release of PS from the various
types of gel beads into 0.1 M phosphate buffer (pH 7.2) was
determined. Dried CS gel beads, corresponding to 1 g of hy-
drogel, and 1 g of Alg hydrogel beads were added to 500 ml
of dissolution medium in a JP XIII dissolution test apparatus
(paddle method, 100 rpm, 37 °C). A 4 ml aliquot of the solu-
tion was removed periodically for analysis and replaced with
4 ml of the dissolution medium (pre-warmed to 37 °C) to
maintain a constant volume. The absorbance of each sample
was determined with a Hitachi model 200-20 spectropho-
tometer at 246 nm. All the dissolution tests were performed
in triplicate.
In Vivo Degradation of CS Gel Beads The biodegrada-
tion of CS gel beads implanted into mice and the in vivo re-
lease of PS were investigated as follows. Air (3 ml) was in-
jected subcutaneously into the dorsal surface of mice (ddy,
male, 5—6-weeks-old) to form AP. An oval AP was formed
after an additional 1 ml of air was injected at 1 and 4 d. A
grain of beads was implanted into the AP under anesthesia
with ether 7 d after the first injection of air. The beads were
retrieved from the AP after 1 and 3 d, and contents of the AP
were collected by washing with 1 ml of physiological saline
three times under anesthesia with pentobarbital sodium. The
abdominal skin was then opened and blood was collected
from the vena cava caudalis. The PS concentration in plasma
and the amount of PS in the gel beads and AP were deter-
mined. The protein content of the AP was also determined by
the method of Lowry.12)
Determination of Plasma PS Concentration Blood
samples were centrifuged at 3500 rpm for 5 min. Supernatant
(100 m l) was then added to 500 m l of 20% trichloroacetic acid
aqueous solution to remove protein, 200 m l of 4 mg/ml methyl
p-hydroxybenzoate aqueous solution as internal standard, and
200 m l of distilled/demineralized water. The mixture was
centrifuged at 3500 rpm for 5 min, and the supernatant was
then loaded into a sample extraction product (OASIS HLB,
Waters). The extracted sample was subjected to high-perfor-
mance liquid chromatography (HPLC). A 20 m l aliquot of the
sample was loaded onto a column (YMC-Pack Pro C18;
150 mm33.0 mm), and eluted with 25% tetrahydrofuran
(THF) aqueous solution as the mobile phase at a flow rate of
0.3 ml/min (Shimadzu LC-10AS). PS in the effluent from the
column was detected at 246 nm with a UV spectrophotome-
ter (Shimadzu SPD-10AVVP).
Determination of PS in the Gel Beads CS gel beads
were dissolved in 2 ml of 0.1 M acetate buffer (pH 4.5), and
Alg gel beads were dissolved in 2 ml of 1% tetra-sodium eth-
ylenediaminetetraacetate. These samples were added to 50 m l
of 200 mg/ml internal standard made up in 25% THF aque-
ous solution, and made up to 5 ml with 25% THF aqueous
solution. The mixture was centrifuged at 3500 rpm for 5 min,
and the supernatant was filtered (Cosmonice Filter S, 0.5 mm,
Millipore) and subjected to HPLC as described above.
Determination of PS in the AP The AP contents were
added to 50 m l of 200 mg/ml internal standard made up in
25% THF aqueous solution, and made up to 5 ml with physi-
ological saline. The protein concentration was then deter-
mined by the method of Lowry using 350 m l of the mixture.
One milliliter of the mixture was added to 1 ml of 50%
MeOH and centrifuged at 3500 rpm for 5 min. The super-
natant was filtered (Cosmonice Filter S, 0.5 mm, Millipore)
and subjected to HPLC as described above.
RESULTS AND DISCUSSION
Preparation of CS Gel Beads Preparation of the CS gel
beads was affected by the properties of the CS (Table 1). The
optimum concentrations for the formation of gel spheres
were 1% for both CS7B and CS8B, and 1.5% and 2% for
CS9B. Lower concentrations of CS did not form gel spheres
and higher concentrations were difficult to drop by pipette
due to their high viscosity.
Evaluation of Biocompatibility The amount of protein
in the AP 3 d after implantation of CS gel beads without PS
was determined to evaluate the inflammatory response (Fig.
1). No increase in protein was observed in the AP compared
with injection of 30 mg carrageenin with 1 ml of physiologi-
cal saline which is known to induce inflammation. This may
indicate that the CS gel beads were biocompatible.
In Vivo Degradation of CS Gel Beads It is known that
mucopolysaccharides are degraded by hydrolysis by enzymes
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Table 1. Relationship between CS Properties and Gel Formation
Degree of Concentration of CS (%)
CS species deacetylation 
Molecular
(%)
weighta)
0.5 1.0 1.5 2.0
7B 70 2210000 2 1 11 11
(66) (610) (8750) (34940)
8B 80 2140000 2 1 11 11
(52) (400) (3340) (33600)
9B 90 900000 2 2 1 1
(24) (170) (740) (1210)
10B 100 950000 2 2 2 2
(9) (25) (21) (18)
a) Ref. 1. Gel formation: 2 no gelation; 1 gelation; 11 difficult to drop (high viscosity). ( ):Viscosity (cps), determined on CS solution at 37 °C using a B type viscometer
(Tokyokeiki).
such as lysozyme. In a previous study, CS gel beads were de-
graded in 0.1 M phosphate buffer containing lysozyme. CS7B
gel beads began to degrade after 3 d, although with CS8B
only slight degradation was noted after 28 d.10) In this study,
in vivo degradation of CS gel beads in the AP occurred faster
than that in vitro. Degradation of the CS gel beads was accel-
erated as their degree of deacetylation decreased. Some
CS7B gel beads in the AP were degraded within 1 d, al-
though with CS8B degradation was not observed this
quickly. Both CS7B and CS8B gel beads in the AP were de-
graded in less than 3 d after implantation, however Jameela
and Jayakrishnan5) described that CS (deacetylation: 74%)
microspheres, cross-linked by glutaraldehyde, were not de-
graded 12 weeks after implantation in rat muscle. On the
other hand, Tomihata and Ikada3) reported that CS films, pre-
pared by the solution casting method, were degraded within 4
weeks in the case of chitin and CS (deacetylation: 68.8%),
and CS films which were .73% deacetylated were not de-
graded after 12 weeks subcutaneously on the dorsal surface
of rats. Degradation may be affected by enzymes, body con-
stituents, the conditions of application and the structure of
the gel matrix, although the reasons for this are not clear. It
was possible, however, to control the in vivo degradability of
CS gel beads by considering the differences in degradability
of the various types of CS with different degrees of deacety-
lation. CS9B (1.5%) gel beads were not degraded in the AP
after 3 d. The degradability of CS gel beads could also be
controlled by changing the CS concentration. CS9B (2%) gel
beads degraded less than 1.5% beads after 3 d.
In Vivo Release of PS from CS Gel Beads The in vivo
release of PS from gel beads was evaluated by measuring the
percentage of residual PS in the gel beads and AP compared
with the amount administered. When 1% PS suspended in
physiological saline was injected into the AP, PS disappeared
immediately from the site and the residual amount was 0.2%
after 24 h (Table 2). The plasma level also changed gradually
according to the amount of PS in the AP, indicating that PS
in the AP passed rapidly into the blood stream. This rapid
disappearance was also recognized when PS was suspended
in CS7B acetate buffer solution (pH 4.5) and injected into the
AP. As shown in Table 3, the reduction in PS was faster be-
cause the CS solution was more viscous than saline. A simi-
lar result was obtained with CS8B solution. No retention of
PS in the AP occurred even with viscous CS. These results
show that when PS powder is dissolved in the exudate in AP
it does not remain there for long. To reduce the side-effects
and prolong the duration of activity of a drug it is therefore
necessary to employ a vehicle to administer the drug. PS was
released more gradually from Alg gel beads and little re-
mained after 3 d, although the beads did not degrade over 7 d
in the AP. Thus, control of drug release is as important as
control of gel degradation. As shown in Fig. 2, 1% CS7B,
CS8B and 1.5% CS9B gel beads showed similar PS release
profiles to Alg gel beads. However, as shown in Table 4, the
release of drug in the AP was affected by degradability of the
CS gel beads. In the case of 1% CS7B gel beads, about 70%
of the PS was released after 1 d, and all of the PS had been
released from 1% CS7B and CS8B gel beads before 3 d as
degradation accelerated. In contrast, release of PS from 1.5%
CS9B gel beads in the AP was similar to that of Alg gel
beads. In addition, the in vivo release of PS from CS9B gel
beads reflected the in vitro release profile as there was no
degradation. Changing the type of CS or increasing the CS
concentration decreased the in vivo release of PS from the
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Fig. 1. Evaluation of Biocompatibility on Inflammatory Response 3 d
after Implantation Determined from the Amount of Protein in the AP
(n53—8)
Control: only incision (no implantation).
Fig. 2. The in Vitro Release Profile of PS from Gel Beads
Table 2. Percentage of Residual PS in the AP after Injection of PS Sus-
pension
After Residual PS Plasma PS 
implantation (h) in the AP ( %) concentration (mg/ml)
1 19.762.8 2.360.5
3 7.262.8 1.260.3
5 2.462.9 0.360.1
24 0.260.1 N.D.
N.D.: not determined (percentage of residual PS in the AP ,0.02%, plasma PS con-
centration ,0.1 mg/ml). Residual PS in the AP (%): residual/administered. Data repre-
sent the mean6S.D. (n55).
Table 3. Percentage of Residual PS in the AP after Injection of PS Sus-
pended in CS Solution
After Residual PS Plasma PS 
implantation CS species in the AP concentration 
(d) (%) (mg/ml)
1 7B 0.560.9 0.260.1
8B 0.460.6 0.260.2
3 7B N.D. N.D.
8B N.D. N.D.
N.D.: not determined (percentage of residual PS in the AP ,0.02%, plasma PS con-
centration ,0.1 mg/ml). Residual PS in the AP (%): residual/administered. Data repre-
sent the mean6S.D. (n55).
gel beads. The in vivo release of PS from 2% CS9B was sus-
tained, and 76% and 27% of administered PS remained in the
gel beads after 1 and 3 d, respectively.
These results show that PS release in the AP is governed
by both diffusion and degradation of the gel matrix. The con-
trol of biodegradation and drug release from a vehicle will
make possible the supply of the minimum requirement of a
dose by local application, and may result in a prolongation of
the duration of drug activity and a reduction of the side ef-
fects. In a previous study, control of drug release from CS gel
beads in vitro was achieved by application of an electrostatic
complex formed between chondroitin sulfate and CS. Degra-
dation and drug release of the CS gel beads can be controlled
by modifying the structure of the gel matrix. Thus, these
beads appear promising as a biodegradable vehicle for sus-
tained drug delivery.
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Table 4. Effect of Gel Species on the Percentage of Residual PS in the Gel
Beads
After Residual PS Residual PS Plasma PS
implantation 
Gel 
in the gel beads in the AP concentration 
(d)
species
(%) (%) (mg/ml)
1 1% 7B 31.5620.0 6.2365.74 0.160.1
1% 8B 52.36 8.3 0.2460.04 N.D.
1.5% 9B 64.46 5.7 0.4860.71 N.D.
2% 9B 76.56 9.2 0.1560.03 N.D.
Alg 48.0611.1 0.1260.03 N.D.
3 1% 7B Degraded N.D. N.D.
1% 8B Degraded N.D. N.D.
1.5% 9B 1.36 1.8 N.D. N.D.
2% 9B 27.26 9.7 0.0560.05 N.D.
Alg 2.36 2.1 0.0360.04 N.D.
N.D.: not determined (percentage of residual PS in the gel beads and the AP
,0.02%, plasma PS concentration ,0.1 mg/ml). Residual PS in the gel beads and the
AP (%): residual/administered. Data represent the mean6S.D. (n55).
